116 related articles for article (PubMed ID: 32460859)
21. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
22. Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study.
Stenman C; Abrahamsson E; Redsäter M; Gnanapragasam VJ; Bratt O
Eur Urol Open Sci; 2022 Jul; 41():123-125. PubMed ID: 35722245
[TBL] [Abstract][Full Text] [Related]
23. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.
Pettersson A; Robinson D; Garmo H; Holmberg L; Stattin P
Ann Oncol; 2018 Feb; 29(2):377-385. PubMed ID: 29161337
[TBL] [Abstract][Full Text] [Related]
24. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.
Abdollah F; Schmitges J; Sun M; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Int J Urol; 2012 Sep; 19(9):836-44. PubMed ID: 22574746
[TBL] [Abstract][Full Text] [Related]
25. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
26. TXNIP hypomethylation and its interaction with obesity and hypertriglyceridemia increase type 2 diabetes mellitus risk: A nested case-control study.
Zhang D; Cheng C; Cao M; Wang T; Chen X; Zhao Y; Wang B; Ren Y; Liu D; Liu L; Chen X; Liu F; Zhou Q; Tian G; Li Q; Guo C; Li H; Wang J; Cheng R; Hu D; Zhang M
J Diabetes; 2020 Jul; 12(7):512-520. PubMed ID: 31919985
[TBL] [Abstract][Full Text] [Related]
27. Hypomethylation of the Interferon γ Gene as a Potential Risk Factor for Essential Hypertension: A Case-Control Study.
Bao XJ; Mao SQ; Gu TL; Zheng SY; Zhao JS; Zhang LN
Tohoku J Exp Med; 2018 Apr; 244(4):283-290. PubMed ID: 29643275
[TBL] [Abstract][Full Text] [Related]
28. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
[TBL] [Abstract][Full Text] [Related]
29. Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England.
Parry MG; Boyle JM; Nossiter J; Morris M; Sujenthiran A; Berry B; Cathcart P; Aggarwal A; van der Meulen J; Payne H; Clarke NW
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):257-263. PubMed ID: 34493837
[TBL] [Abstract][Full Text] [Related]
30. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Ilic D; Evans SM; Allan CA; Jung JH; Murphy D; Frydenberg M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009625. PubMed ID: 28895658
[TBL] [Abstract][Full Text] [Related]
31. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis.
Meurs P; Galvin R; Fanning DM; Fahey T
BJU Int; 2013 Mar; 111(3):427-36. PubMed ID: 22882877
[TBL] [Abstract][Full Text] [Related]
33. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
34. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
35. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
37. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
38. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
39. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
Dall'Era MA; Lo MJ; Chen J; Cress R; Hamilton AS
Cancer; 2018 May; 124(9):1921-1928. PubMed ID: 29499075
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]